Incidence, Prevalence, and Mortality of Dermatomyositis in Adults Determined
Using the ACR/EULAR criteria, researchers studied the population-based incidence, prevalence, and mortality of dermatomyositis in adults.
Using the ACR/EULAR criteria, researchers studied the population-based incidence, prevalence, and mortality of dermatomyositis in adults.
The FDA has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.
Researchers investigated the content validity of patient-reported outcome measures in patients with idiopathic inflammatory myopathies.
Authors of a report presented the case of systemic sclerosis-polymyositis overlap syndrome in an adolescent with anti-Ku antibodies.
Researchers identified independent predictors of short-term dermatomyositis- or polymyositis-related interstitial lung disease mortality.
Factors associated with favorable treatment responses to conventional therapy and tacrolimus in myositis-associated interstitial lung disease were examined in a retrospective cohort study.
The relationship between PM and ALS could indicate a common pathophysiology.
Patients with PM or DM had an increased prevalence of cardiac abnormalities, most commonly left ventricular diastolic dysfunction, compared with healthy controls.
Five randomized controlled trials including adult patients with polymyositis and dermatomyositis (DM) and additional open studies have demonstrated reduced impairment and activity limitation as well as improved quality of life. Exercise can improve muscle aerobic capacity as shown by increased mitochondrial enzyme activity. These data suggest that intensive aerobic exercise and resistance training could reduce disease activity and inflammation and improve muscle metabolism.